Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 3Breast Neoplasms 2Solid Tumours 1Side-effect of Antibiotic 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Long QT Syndrome 1Hot Flashes 1Hodgkin Disease 1Carcinoma, Renal Cell 1Bacteremia 1Advanced Breast Cancer 1

Interventions

Gabapentin 6Acupuncture Therapy 4Venlafaxine Hydrochloride 3liposomal amphotericin B 2Tamoxifen 2Magnesium Oxide 2Isoflavones 2Citalopram 2Caspofungin 2zopiclone 1oxybutynin 1black cohosh root extract 1Zolpidem 1Vitamin B 6 1Vancomycin 1Testosterone 1Tazobactam 1Soybean Proteins 1Sodium Chloride 1Sertraline 1Pregabalin 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine 1Moxifloxacin 1Mindfulness-Based Stress Reduction 1Mindfulness 1Mind-Body Therapies 1Megestrol Acetate 1Medroxyprogesterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hot Flashes × Moxifloxacin × Clear all
NCT05481528 2023-05-09

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

Bayer

Phase 1 Completed
51 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡